[Efficacy of @entity800 in sexually transmitted male XXXX and @entity3799 ].

@entity6369 @entity1 @entity2954 @entity7566 @entity2953 @entity19001 @entity281 @entity3799 @entity800 @entity1536
Efficacy and safety of @entity800 ( @entity19001 ), a new @entity1536 antibacterial agent, were investigated in cases of sexually transmitted male @entity6369 and @entity3799 . @entity281 occupied a large part of the @entity1 enrolled. This study was conducted in 29 institutions. A total of 1,126 @entity1 with @entity2954 , chlamydial or non- @entity2954 non- @entity281 were enrolled in the study. The general dosing regimen of oral @entity19001 was 100 mg t.i.d. or 200 mg t.i.d. for 14 consecutive days. Along with the clinical efficacy evaluated by doctors in charge, therapeutic and clinical efficacies were determined according to standardized evaluation criteria. The evaluation of therapeutic efficacy was based on bacterial eradication. On the other hand, clinical efficacy was determined upon the improvement in causative bacteria, WBC counts in smear (or initial urine) specimens and urethra/cervical discharges. Clinical efficacy was determined on 7 and 14 days after starting the medication, except for @entity2954 for which the efficacy was determined on Day 3 and Day 7. The results obtained are summarized as follows. 1. Efficacy evaluation by standardized criteria Therapeutic efficacy rates in @entity2954 were 97.9% (93/95) on Day 3 and 100% (119/119) on Day 7. In @entity281 , the rates were 77.7% (363/467) on Day 7 and 93.6% (392/419) on Day 14. @entity7566 rated 94.8% (239/252) and @entity3799 91.6% (153/167) on Day 14. Clinical efficacy rates in @entity2954 were 63.2% (60/95) on Day 3 and 95.8% (114/119) on Day 7. In @entity281 , they were 70.0% (327/467) on Day 7 and 89.7% (376/419) on Day 14. @entity7566 rated 88.5% (223/252) and @entity3799 91.6% (153/167) on Day 14. Clinical efficacy rates in non- @entity2954 non- @entity281 were 93.3% (97/104) for male @entity6369 and 65.9% (27/41) for @entity3799 on Day 14. 2. Clinical efficacy determined by doctors in charge A total of 1,028 cases, 752 @entity6369 and 276 @entity3799 cases, was evaluated by doctors in charge. Clinical efficacy rates were 90.3% for @entity6369 and 92.4% for @entity3799 . 3. Safety Safety evaluations was conducted in 1,087 @entity1 . Side effects were observed in 23 @entity1 among them (2.12%). None of them were deemed serious. General laboratory examinations were conducted for 169 @entity1 . Abnormal findings were seen in 11 @entity1 (6.51%) or 13 cases, all of which were minor. The results of this multi-center clinical trial demonstrated that @entity19001 is effective and well tolerated in the treatment of @entity2953 ( @entity2953 ), both @entity2954 .
